ArticlemedRxiv : the preprint server for health sciences2025
Prevalence of deleterious cardiomyopathy variants in early-onset atrial fibrillation.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is a common cardiac arrhythmia associated with an increased risk of stroke, heart failure, and death. Recent studies suggests that individuals with early onset of AF could be at increased risk of developing heart failure and dilated cardiomyopathy. This study aimed to identifying genetic variants in a broad panel of cardiomyopathy genes among early-onset AF individuals. Methods: We conducted targeted genetic sequencing of 29 cardiomyopathy-associated genes in 478 individuals with AF onset below 45 years of age from a Danish cohort. Additionally, we analyzed whole exome sequencing data in 374,289 individuals from the UK Biobank, including 29,108 individuals with AF. The cohort was stratified by age at AF diagnosis, and individuals with pre-existing cardiomyopathy were excluded. We focused on rare, truncating variants predicted to lead to loss of function, and potentially deleterious missense variants in the UK Biobank. Results: In the Danish cohort, 42 (8.8%) individuals with early-onset AF had truncating genetic variants in known cardiomyopathy genes. The UK Biobank analysis showed an inverse dose-response-like relationship between age of AF onset and prevalence of truncating variants, ranging from 3.8% in the AF onset <45 years group to 1.4% in the group without AF diagnosis. The prevalence of rare missense variants showed a similar pattern. Conclusions: We identified a high prevalence of deleterious variants in cardiomyopathy-associated genes among individuals with early-onset AF. This supports recent guideline suggestions and indicates that genetic testing and surveillance for cardiomyopathy could be relevant in selected individuals with an early AF diagnosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.